InfuSystems (INFU) vs Neuropace (NPCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
InfuSystems (INFU) has outperformed Neuropace (NPCE) over the past year, gaining 51.7% versus a loss of 44.6%. Over five years, INFU leads with a -15.9% price change compared with -32.8% for NPCE. InfuSystems is the larger company by market cap ($287.5 million vs $273.9 million), about 1.0 times the size, while Neuropace is growing revenue faster (+25.1% vs +6.4%).
InfuSystems converts more of its revenue into profit, with a net margin of 4.6% versus -21.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INFU | NPCE |
|---|---|---|
| Share price | $14.35 | $7.95 |
| Market cap | $287.48M | $273.89M |
| 1-day change | +2.06% | -2.33% |
| YTD return | +59.98% | -48.51% |
| 1-year return | +51.69% | -44.60% |
| 5-year return | -15.93% | -32.80% |
| P/E ratio (TTM) | 32.61 | — |
| Forward P/E | 25.63 | — |
| EPS (TTM) | $0.44 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $143.44M | $99.99M |
| Revenue growth (YoY) | +6.36% | +25.13% |
| Net income (latest FY) | $6.63M | $-21.46M |
| Gross margin | 55.98% | 77.23% |
| Operating margin | 8.31% | -16.34% |
| Net margin | 4.62% | -21.47% |
| 52-week high | $15.47 | $19.60 |
| 52-week low | $7.29 | $5.46 |
| Distance from 52-week high | -7.24% | -59.44% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +28.92% | +53.71% |
| Average volume | 136.60K | 270.76K |
| Shares outstanding | 20.03M | 34.45M |
| Employees | 461 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed NPCE by 96.3 percentage points over the past year.
- InfuSystems is more profitable, keeping 4.6 cents of every revenue dollar as net income versus -21.5 cents for Neuropace.
- Neuropace grew revenue faster in its latest fiscal year (+25.13% vs +6.36%).
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 216 employees
INFU vs NPCE FAQ
Which is bigger, InfuSystems or Neuropace?
InfuSystems (INFU) is larger, with a market capitalization of $287.48M compared with $273.89M for Neuropace (NPCE).
Which stock has performed better over the past year, INFU or NPCE?
INFU returned +51.69% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.
Are InfuSystems and Neuropace in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.